

**FITC anti-human CD19**

**Catalog # /** 2562535 / 25 tests  
**Size:** 2562540 / 100 tests

**Clone:** 4G7

**Isotype:** Mouse IgG1,  $\kappa$

**Immunogen:** Human Chronic Lymphocytic Leukemia (CLL) cells


**Reactivity:** Human

**Preparation:** The antibody was purified by affinity chromatography and conjugated with FITC under optimal conditions. The solution is free of unconjugated FITC and unconjugated antibody.

**Formulation:** Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA).

**Workshop Number:** HCDM listed

**Concentration:** Lot-specific



Human peripheral blood lymphocytes were stained with CD19 (clone 4G7) FITC (filled histogram) or Mouse IgG1,  $\kappa$  FITC isotype control (open histogram).

**Applications:**

**Applications:** Flow Cytometry

**Recommended Usage:** Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5  $\mu$ l per million cells or 5  $\mu$ l per 100  $\mu$ l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

**Application References:** 1. Tedder T, *et al.* 1994. *Immunol. Today* 15:437.  
2. Bradbury L, *et al.* 1993. *J. Immunol.* 151:2915.

**Description:** CD19 is a 95 kD type I transmembrane glycoprotein also known as B4. It is a member of the immunoglobulin superfamily expressed on B-cells (from pro-B to blastoid B cells, absent on plasma cells) and follicular dendritic cells. CD19 is involved in B cell development, activation, and differentiation. CD19 forms a complex with CD21 (CR2) and CD81 (TAPA-1), and functions as a BCR co-receptor.

**Antigen References:** 1. Tedder T, *et al.* 1994. *Immunol. Today* 15:437.  
2. Bradbury L, *et al.* 1993. *J. Immunol.* 151:2915.